Answers are grounded in this paper and cite their sources.
Gene therapy demonstrates delayed disease onset and preserved function in ALS mouse model, suggesting new treatment pathways.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with limited treatment options. Mutations in SOD1 are a leading genetic cause of familial ALS, driving motor neuron degeneration through toxic gain-of-function mechanisms. While gene silencing strategies targeting SOD1 hold therapeutic promise, their clinical translation has been hindered by inefficient delivery to the spinal cord and safety concerns associated with conventional viral vectors. Here, we report a minimally invasive gene therapy strategy that combines the retrograde transport capability of rAAV2-retro with the safety of an artificial microRNA (miRNA) to achieve pan-spinal SOD1 suppression. A single intramuscular injection of rAAV2-retro-miRNA into neonatal SOD1G93A mice resulted in widespread transduction of spinal motor neurons, significant reduction of mutant SOD1 protein, and multifaceted therapeutic benefits. Treated mice exhibited delayed disease onset, extended survival, preserved motor function, reduced neuroinflammation, and protection of neuromuscular junctions and spinal motor neurons. Importantly, the artificial miRNA platform demonstrated a superior safety profile compared to shRNA-based constructs, which caused severe toxicity and lethality in wild-type mice. Our study establishes neonatal intramuscular delivery of rAAV2-retro-miRNA as a safe, efficient, and clinically translatable strategy for preemptive intervention in SOD1-mediated ALS, with broad implications for the treatment of other motor neuron diseases.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: